Anti-Mouse CD40 (Clone 65924)

Quality Tested by Leinco ELISA Sandwich: This antibody is useful as the capture antibody in a sandwich ELISA. The suggested coating concentration is 2-8 µg/ml. A suitable detection antibody is PN:C1499 at a concentration of approximately 0.1-0.4 µg/ml. A suggested standard for this assay is PN:C1336.
Flow Cytometry: It is recommended to use the indirect method for signal enhancement when enumerating cells expressing CD40. A suggested method would be to stain cells expressing CD40 with 0.25 µg per 1 - 2.5 x 10⁶ cells in a total staining volume of ≤200 µl followed by PN:R485.
Western Blotting: To detect Mouse CD40 this monoclonal antibody can be used at a concentration of 1-2 µg/ml. This monoclonal antibody should be used in conjunction with compatible second-step reagents such as PN:R377 and a chromogenic substrate such as PN:T343. The detection limit for Mouse CD40 is 0.2 ng/lane under either reducing or non-reducing conditions. The sensitivity of detection may increase up to 50 fold when a chemiluminescent substrate is used. A suitable Western blotting control is PN:C1336.

CD40

Next Day Ambient

CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40, in association with its ligand CD154 (CD40L) - a 39 kD protein, acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen presenting cells. CD40 is involved in Ig isotype switching and dendritic cell maturation, as well as the activation, differentiation and proliferation of B cells. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy. Blocking the interaction of CD40 with its ligand (CD154) is the sought-after therapeutic objective for preventing and/or improving both autoimmune diseases and transplant rejection. Studies have shown that monoclonal antibodies that block CD154 in human clinical trials resulted in unanticipated vascular complications. Hence, an interest in the therapeutic potential for antagonist mAbs specific for human CD40 is emerging. Antibodies of particular therapeutic interest are those that do not inhibit CD40 signaling via physical competition with CD154. Additionally, the interaction of CD40 and its ligand (CD154) is found to be essential for amyloid-beta-induced microglial activation, thus plays a significant part in Alzheimer disease pathogenesis.

CyTOF-ready:Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Clone 65924 recognizes an epitope on mouse CD40.

This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.4 containing 5.0% w/v trehalose.

Purified Recombinant Mouse CD40 (> 98%)